Skip to main content
  • Home
  • Synopsis Article Listing
  • Predictors of atrial fibrillation development in patients with embolic stroke of undetermined source: An analysis of the RE-SPECT ESUS trial

Predictors of atrial fibrillation development in patients with embolic stroke of undetermined source: An analysis of the RE-SPECT ESUS trial

What was known?

Embolic stroke of undetermined source (ESUS) is associated with a stroke recurrence rate of 3% to 6% per year. Patients with ESUS have also been found to have a high incidence of atrial fibrillation (AF), suggesting that AF may be an underlying cause of stroke recurrence. Known predictors of AF after stroke include clinical characteristics, findings on Holter monitoring and echocardiographic measurements. Detection of AF in these patients is important because it affects the management strategy.

Objective(s):

The aim of this study was to assess clinical factors predicting the development of AF and associated recurrent stroke in patients with ESUS.

What this study adds:

This study has identified a patient subgroup that can be identified through simple clinical variables and may benefit from prolonged cardiac monitoring for detection of AF. 

Clinical implications:

Among patients with ESUS, around 7.5% will develop AF over the next 19 months. Risk factors for development of AF in ESUS patients include older age, higher body mass index (BMI), hypertension, absence of diabetes, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels. For patients with these risk factors for developing AF after ESUS, long-term cardiac monitoring may be beneficial.

Study design:

This is a secondary analysis of the RE-SPECT ESUS study (NCT02239120), which was an international, double-blind Phase III trial in which patients (n=5390) with recent ESUS were randomly assigned to receive dabigatran and aspirin placebo or aspirin and dabigatran placebo. AF was identified through investigators’ standard of care and by 1-year electrocardiography (ECG). NT-proBNP level was evaluated as an AF predictor for a subset of patients (n = 1,117) who had a baseline level available.

Primary endpoints:

  • Recurrent stroke of ischaemic, haemorrhagic, or unspecified type, assessed in a time-to-event analysis.
  • Major bleeding according to International Society on Thrombosis and Haemostasis  criteria, assessed in a time-to-event analysis

Secondary endpoints:

  • Adjudicated ischaemic stroke

Inclusion criteria:

  • Ischaemic stroke with a brain lesion visualized by neuroimaging (either brain Computed Tomography [CT] or Magnetic Resonance Image [MRI])
  • The index stroke must have occurred either up to 3 months before randomisation (Modified Rankin Scale[mRS] ≤3 at randomisation) or up to 6 months before randomisation (mRS ≤3 at randomisation) in selected patients aged ≥60 years, plus at least one additional risk factor for recurrent stroke.

Notable exclusion criteria:

  • Modified Rankin Scale of ≥4 at randomisation or inability to swallow medications.
  • Major risk cardioembolic source of embolism including: intracardiac thrombus diagnosed by transthoracic or transesophageal echocardiography; paroxysmal, persistent or permanent AF;  atrial flutter; prosthetic cardiac valve (mitral or aortic, bioprosthetic or mechanical); atrial myxoma: other cardiac tumours; moderate or severe mitral stenosis; recent (< 4weeks) myocardial infarction; valvular vegetations, or infective endocarditis

Findings:

  • Of the 5390 participants, 403 (7.5%) developed AF during follow-up
  • In the multivariate model, independent predictors of developing AF after ESUS during the study were: older age (odds ratio [OR] for 10-year increase, 1.99; 95% confidence interval [CI], 1.78–2.23]; p<0.001), hypertension (OR, 1.29; 95% CI, 1.16–1.44; p=0.0304), diabetes (OR, 0.74; 95% CI, 0.56–0.96; p=0.0226), and body mass index (OR  for 5-U increase, 1.29; 95% CI, 1.16–1.43; p<0.001)
  • In a sensitivity analysis of 1117 patients with baseline NT-proBNP measurements, only older age and higher NT-proBNP were significant independent predictors of AF
  • CHA2DS2-VASc scores were higher in patients with AF compared with those without AF.

Interpretation:

In this study, older age, higher BMI, hypertension, and absence of diabetes were associated with a higher risk of developing AF. When baseline NT-proBNP was available, only older age and elevation of this biomarker were significant predictors of AF. The rate of recurrent stroke in patients who developed AF was higher than in the entire group. This emphasises the importance of detection and treatment of AF in patients who have had ESUS. Simple clinical variables and, when available, levels of NT-proBNP could help identify a patient population who may benefit from prolonged cardiac monitoring. However, these data should be considered hypothesis-generating and not conclusive, as they are vulnerable to detection bias. Further study is warranted to assess the clinical utility of NT-proBNP as a biomarker of risk in this setting.

Limitations:

  • This is a secondary analysis that is hypothesis-generating only
  • Detection of AF during follow-up was not done systematically but according to standard of care, apart from the systematically collected, yearly 12-lead ECGs
  • Biomarkers were only available in 20% of the patient population, limiting assessments of the association of NT-proBNP with the risk of stroke

Related Content

RIO 2020 – COMPLEX ARRHYTHMIAS MADE SIMPLE: ABLATION OF STRUCTURAL HEART VT
  • 1.00 EBAC

Learning objectives

  • Discuss the merits of using ablation in the day surgery setting and as a first-line treatment for atrial fibrillation
  • Summarise recent clinical data on emerging ablative techniques for atrial fibrillation and ventricular tachycardia (VT)
  • Recall how to carry out ablative procedures including fluoro-free ablation, high power ablation, ablation of structural heart VT, convergent ablation and ablation in atrial tachycardia
  • Recall how to carry out leadless pacing and His bundle pacing for cardiac synchrony
See more
Dual antiplatelet therapy for acute stroke and TIA
  • 1.00 EBAC

Learning objectives

  • To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
  • To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
  • To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice
See more
Convergent Procedure for Atrial Fibrillation
  • 1.00 EBAC

Learning objectives

  • Discuss the need for optimal approaches to atrial ablation and identify patients for whom a convergent procedure approach is indicated
  • Describe the convergent procedure and the role of electrophysiologist and surgeon
  • Discuss current clinical understanding of the convergent procedure including emerging data and the role of the left atrial appendage in ablation
See more
Convergent procedure: A new approach to atrial fibrillation ablation
  • 1.00 EBAC

Learning objectives

  • After this session electrophysiologists will be able to identify the causes of sub-optimal outcomes in atrial ablation, describe the convergent procedure and appropriate patients, and outline the electrophysiologist’s role.
See more
Hybrid ablation: a role in AF management?
  • 1.00 EBAC

Learning objectives

  • Define the clinical value of a multidisciplinary “AF Heart Team”.
  • Analyse the scientific evidence that supports the safety and efficacy of hybrid ablation techniques.
  • Propose how to effectively implement a hybrid approach to managing AF in their clinical practice.
See more
Utilizing NOAC's in non-valvular atrial fibrillation patients undergoing PCI

Learning objectives

  • Describe the complex nature and current recommendations for antithrombotic therapy for non-valvular AF patients undergoing PCI
  • Define the complications associated with TAT
  • Summarize the latest data utilizing NOAC therapy in AF patients undergoing PCI
See more
RIO 2020 – AF ABLATION MADE SIMPLE: PRESENTATION SESSIONS
  • 1.00 EBAC

Learning objectives

  • Discuss the merits of using ablation in the day surgery setting and as a first-line treatment for atrial fibrillation
  • Summarise recent clinical data on emerging ablative techniques for atrial fibrillation and ventricular tachycardia (VT)
  • Recall how to carry out ablative procedures including fluoro-free ablation, high power ablation, ablation of structural heart VT, convergent ablation and ablation in atrial tachycardia
  • Recall how to carry out leadless pacing and His bundle pacing for cardiac synchrony
See more
RIO 2020 – DEVICES: LEADLESS PACING TO ACHIEVE SYNCHRONY IN 20 MINUTES
  • 1.00 EBAC

Learning objectives

  • Discuss the merits of using ablation in the day surgery setting and as a first-line treatment for atrial fibrillation
  • Summarise recent clinical data on emerging ablative techniques for atrial fibrillation and ventricular tachycardia (VT)
  • Recall how to carry out ablative procedures including fluoro-free ablation, high power ablation, ablation of structural heart VT, convergent ablation and ablation in atrial tachycardia
  • Recall how to carry out leadless pacing and His bundle pacing for cardiac synchrony
See more